MedTrace Logo

Intralesional Ranibizumab on Pterygium Vascularity, Size and Recurrence Rate: a Pilot Study

NCT02342392 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2015-01-19

No results posted yet for this study

Summary

The purpose of this study is to evaluate the pterygium vascularity and size before and after intralesional ranibizumab injection and to evaluate its recurrence rate following pterygium excision surgery.

Conditions

  • Pterygium

Interventions

DRUG

ranibizumab

Intralesional ranibizumab 0.3 mg/0.03mL injected 1 week before pterygium excision surgery.

Sponsors & Collaborators

  • Universiti Sains Malaysia

    lead OTHER

Principal Investigators

  • Hao Chi Ho, MD · Hospital Universiti Sains Malaysia

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-09-30
Primary Completion
2014-09-30
Completion
2014-09-30

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02342392 on ClinicalTrials.gov